• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PSMA 靶向还原裂解超支化聚酰胺-胺基因传递系统治疗前列腺癌骨转移。

PSMA-Targeting Reduction-Cleavable Hyperbranched Polyamide-Amine Gene Delivery System to Treat the Bone Metastases of Prostate Cancer.

机构信息

Department of Orthopedic Surgery, Guangdong Provincial Key Laboratory of Orthopaedics and Traumatology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangzhou, Guangdong Province 510080, People's Republic of China.

Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Department of Biomedical Engineering, Jinan University, Guangzhou 510632, People's Republic of China.

出版信息

Int J Nanomedicine. 2020 Sep 28;15:7173-7184. doi: 10.2147/IJN.S268398. eCollection 2020.

DOI:10.2147/IJN.S268398
PMID:33061374
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7533908/
Abstract

OBJECTIVE

This study aimed to develop aptamer-anchored hyperbranched poly(amido amine) (HPAA) for the systemic delivery of and to evaluate its therapeutic potential against bone metastasis of prostate cancer in vivo and in vitro.

METHODS

A glutathione (GSH)-responsive cationic HPAA was prepared by the Michael addition reaction. Furthermore, HPAA-PEG was produced by PEGylation, and then the aptamer targeted to prostate-specific membrane antigen (PSMA) was conjugated to the HPAA-PEG. The obtained HPAA-PEG-APT could form nanocomplexes with through electrostatic adsorption.

RESULTS

The results of immunocytochemistry indicated that the complexes could target PSMA-expressing LNCaP cells. The ability of HPAA-PEG-APT to facilitate the delivery of into LNCaP cells was proven, and HPAA-PEG-APT/ demonstrated enhanced antitumor activity, lower cytotoxicity and better biocompatibility in vitro. Moreover, in a tibial injection tumor model, the intravenous injection of the HPAA-PEG-APT/ complex significantly inhibited cancer growth and extended the survival time.

CONCLUSION

This study provided an aptamer-anchored HPAA-loaded gene system to deliver for better therapeutic efficacy of bone metastasis of prostate cancer.

摘要

目的

本研究旨在开发适体锚定的超支化聚（酰胺-胺）（HPAA）用于系统递送，并评估其在体内和体外治疗前列腺癌骨转移的潜力。

方法

通过迈克尔加成反应制备谷胱甘肽（GSH）响应性阳离子 HPAA。此外，通过 PEGylation 制备 HPAA-PEG，然后将针对前列腺特异性膜抗原（PSMA）的适体连接到 HPAA-PEG 上。所得的 HPAA-PEG-APT 可通过静电吸附与 形成纳米复合物。

结果

免疫细胞化学结果表明，该复合物可以靶向表达 PSMA 的 LNCaP 细胞。证明了 HPAA-PEG-APT 能够促进 将 递送至 LNCaP 细胞，并且 HPAA-PEG-APT/显示出增强的抗肿瘤活性、更低的细胞毒性和更好的体外生物相容性。此外，在胫骨注射肿瘤模型中，静脉注射 HPAA-PEG-APT/ 复合物显著抑制了肿瘤生长并延长了存活时间。

结论

本研究提供了一种适体锚定的负载基因的 HPAA 系统，用于递送 ，以提高前列腺癌骨转移的治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/7533908/ecee16b74d14/IJN-15-7173-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/7533908/085e6444b820/IJN-15-7173-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/7533908/3facd52b687a/IJN-15-7173-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/7533908/7a7d88c9c7cc/IJN-15-7173-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/7533908/9c7bf2fc68c4/IJN-15-7173-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/7533908/c7b72df4bade/IJN-15-7173-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/7533908/cc00ef357ad0/IJN-15-7173-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/7533908/ecee16b74d14/IJN-15-7173-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/7533908/085e6444b820/IJN-15-7173-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/7533908/3facd52b687a/IJN-15-7173-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/7533908/7a7d88c9c7cc/IJN-15-7173-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/7533908/9c7bf2fc68c4/IJN-15-7173-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/7533908/c7b72df4bade/IJN-15-7173-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/7533908/cc00ef357ad0/IJN-15-7173-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/841c/7533908/ecee16b74d14/IJN-15-7173-g0007.jpg

相似文献

1
PSMA-Targeting Reduction-Cleavable Hyperbranched Polyamide-Amine Gene Delivery System to Treat the Bone Metastases of Prostate Cancer.PSMA 靶向还原裂解超支化聚酰胺-胺基因传递系统治疗前列腺癌骨转移。
Int J Nanomedicine. 2020 Sep 28;15:7173-7184. doi: 10.2147/IJN.S268398. eCollection 2020.
2
Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.第二代适体偶联 PSMA 靶向递药系统用于前列腺癌治疗。
Int J Nanomedicine. 2011;6:1747-56. doi: 10.2147/IJN.S23747. Epub 2011 Aug 19.
3
Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo.利用适体偶联的去端肽胶原在体外和体内高效递送至骨转移前列腺肿瘤的 micro RNA。
Drug Deliv. 2016;23(3):874-81. doi: 10.3109/10717544.2014.920059. Epub 2014 Jun 3.
4
Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.超声介导的纳米泡破坏（UMND）促进了靶向 A10-3.2 适体和载有 siRNA 的阳离子纳米泡的递送来治疗前列腺癌。
Drug Deliv. 2018 Nov;25(1):226-240. doi: 10.1080/10717544.2017.1422300.
5
Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo.适体修饰纳米颗粒的前列腺癌靶向机制及其体内潜在抗癌作用的研究。
Int J Nanomedicine. 2014 Nov 21;9:5431-40. doi: 10.2147/IJN.S71101. eCollection 2014.
6
Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer.适体偶联载多柔比星单分子胶束用于前列腺癌靶向治疗。
Biomaterials. 2013 Jul;34(21):5244-53. doi: 10.1016/j.biomaterials.2013.03.006. Epub 2013 Apr 11.
7
Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy.适体介导多西他赛通过聚合物纳米颗粒递送至前列腺癌以增强抗肿瘤疗效。
Eur J Pharm Biopharm. 2016 Oct;107:130-41. doi: 10.1016/j.ejpb.2016.07.007. Epub 2016 Jul 5.
8
A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery.一种用于基于纳米颗粒的前列腺肿瘤靶向药物递送的RNA-DNA杂交适配体。
Int J Mol Sci. 2016 Mar 14;17(3):380. doi: 10.3390/ijms17030380.
9
Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling.miR-133a-3p 的下调通过激活 PI3K/AKT 信号通路促进前列腺癌骨转移。
J Exp Clin Cancer Res. 2018 Jul 18;37(1):160. doi: 10.1186/s13046-018-0813-4.
10
Transferrin-targeting redox hyperbranched poly(amido amine)-functionalized graphene oxide for sensitized chemotherapy combined with gene therapy to nasopharyngeal carcinoma.转铁蛋白靶向的氧化还原超支化聚（酰胺-胺）功能化氧化石墨烯用于鼻咽癌的化疗增敏联合基因治疗。
Drug Deliv. 2019 Dec;26(1):744-755. doi: 10.1080/10717544.2019.1642421.

引用本文的文献

1
The crosstalk between glutathione metabolism and non-coding RNAs in cancer progression and treatment resistance.谷胱甘肽代谢与非编码RNA在癌症进展和治疗耐药性中的相互作用。
Redox Biol. 2025 Jul;84:103689. doi: 10.1016/j.redox.2025.103689. Epub 2025 May 19.
2
Tumor microenvironment-responsive hyperbranched polymers for controlled drug delivery.用于可控药物递送的肿瘤微环境响应性超支化聚合物
J Pharm Anal. 2024 Dec;14(12):101003. doi: 10.1016/j.jpha.2024.101003. Epub 2024 May 22.
3
Identification of cell differentiation trajectory-related gene signature to reveal the prognostic significance and immune landscape in prostate cancer based on multiomics analysis.

本文引用的文献

1
Folate-targeting redox hyperbranched poly(amido amine)s delivering MMP-9 siRNA for cancer therapy.靶向叶酸的氧化还原超支化聚（酰胺胺）递送基质金属蛋白酶-9小干扰RNA用于癌症治疗。
J Mater Chem B. 2016 Jan 21;4(3):547-556. doi: 10.1039/c5tb01964h. Epub 2015 Dec 21.
2
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.高风险前列腺癌患者在接受根治性手术或放疗前的前列腺特异性膜抗原 PET-CT（proPSMA）：一项前瞻性、随机、多中心研究。
Lancet. 2020 Apr 11;395(10231):1208-1216. doi: 10.1016/S0140-6736(20)30314-7. Epub 2020 Mar 22.
3
基于多组学分析鉴定细胞分化轨迹相关基因特征以揭示前列腺癌的预后意义和免疫格局
Heliyon. 2024 Mar 8;10(6):e27628. doi: 10.1016/j.heliyon.2024.e27628. eCollection 2024 Mar 30.
4
Controlled siRNA Release of Nanopolyplex for Effective Targeted Anticancer Therapy in Animal Model.纳米多聚物复合物可控 siRNA 释放用于动物模型中有效的靶向抗癌治疗。
Int J Nanomedicine. 2024 Feb 7;19:1145-1161. doi: 10.2147/IJN.S443636. eCollection 2024.
5
Therapeutic potential of targeting mirnas to prostate cancer tumors: using psma as an active target.以微小RNA为靶点治疗前列腺癌肿瘤的潜力：以前列腺特异性膜抗原作为活性靶点
Mol Cell Oncol. 2022 Oct 24;9(1):2136476. doi: 10.1080/23723556.2022.2136476. eCollection 2022.
6
Non-viral vectors for RNA delivery.非病毒载体的 RNA 递送。
J Control Release. 2022 Feb;342:241-279. doi: 10.1016/j.jconrel.2022.01.008. Epub 2022 Jan 10.
7
MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer.微小RNA作为前列腺癌治疗反应的表观遗传决定因素及潜在治疗靶点
Cancers (Basel). 2021 May 14;13(10):2380. doi: 10.3390/cancers13102380.
8
miRNAs as Therapeutic Tools and Biomarkers for Prostate Cancer.微小RNA作为前列腺癌的治疗工具和生物标志物
Pharmaceutics. 2021 Mar 13;13(3):380. doi: 10.3390/pharmaceutics13030380.
Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [Ga]PSMA-PET-guided metastasis-directed therapy.
[镓]PSMA-PET引导的转移灶靶向治疗后寡复发前列腺癌患者生化无复发生存的预后风险分类
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2328-2338. doi: 10.1007/s00259-020-04760-8. Epub 2020 Mar 16.
4
Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study.神经内分泌分化与 PSMA 靶向放射性配体治疗晚期转移性去势抵抗性前列腺癌的反应：一项单中心回顾性研究。
J Nucl Med. 2020 Nov;61(11):1602-1606. doi: 10.2967/jnumed.120.241588. Epub 2020 Mar 13.
5
SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer.SREBP1 siRNA 通过针对骨转移去势抵抗性前列腺癌的骨癌双靶向仿生纳米系统增强多西他赛的疗效。
Theranostics. 2020 Jan 1;10(4):1619-1632. doi: 10.7150/thno.40489. eCollection 2020.
6
Cationic Polymer Nanoparticles-Mediated Delivery of miR-124 Impairs Tumorigenicity of Prostate Cancer Cells.阳离子聚合物纳米颗粒介导的 miR-124 递送抑制前列腺癌细胞的致瘤性。
Int J Mol Sci. 2020 Jan 29;21(3):869. doi: 10.3390/ijms21030869.
7
Programing Assembling/Releasing Multifunctional miRNA Nanomedicine to Treat Prostate Cancer.编程组装/释放多功能 miRNA 纳米药物治疗前列腺癌。
ACS Appl Mater Interfaces. 2020 Feb 26;12(8):9032-9040. doi: 10.1021/acsami.9b21707. Epub 2020 Feb 7.
8
A glutathione-depleting chemodynamic therapy agent with photothermal and photoacoustic properties for tumor theranostics.一种具有光热和光声性能的谷胱甘肽耗竭化学动力学治疗剂，用于肿瘤治疗。
Nanoscale. 2020 Jan 23;12(3):1349-1355. doi: 10.1039/c9nr09858e.
9
Synergistic combination treatment to break cross talk between cancer cells and bone cells to inhibit progression of bone metastasis.协同联合治疗以打破癌细胞与骨细胞之间的串扰，从而抑制骨转移进展。
Biomaterials. 2020 Jan;227:119558. doi: 10.1016/j.biomaterials.2019.119558. Epub 2019 Oct 18.
10
Transferrin-targeting redox hyperbranched poly(amido amine)-functionalized graphene oxide for sensitized chemotherapy combined with gene therapy to nasopharyngeal carcinoma.转铁蛋白靶向的氧化还原超支化聚（酰胺-胺）功能化氧化石墨烯用于鼻咽癌的化疗增敏联合基因治疗。
Drug Deliv. 2019 Dec;26(1):744-755. doi: 10.1080/10717544.2019.1642421.